These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22313340)

  • 1. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.
    Gisondi P; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Girolomoni G; Naldi L;
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e30-41. PubMed ID: 22313340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
    Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
    J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.
    Borghi A; Corazza M; Mantovani L; Bertoldi AM; Giari S; Virgili A
    Int J Dermatol; 2012 Dec; 51(12):1512-6. PubMed ID: 23171021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
    Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.
    Luber AJ; Tsui CL; Heinecke GM; Lebwohl MG; Levitt JO
    J Am Acad Dermatol; 2014 Mar; 70(3):525-32. PubMed ID: 24388425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.
    Naldi L; Addis A; Chimenti S; Giannetti A; Picardo M; Tomino C; Maccarone M; Chatenoud L; Bertuccio P; Caggese E; Cuscito R
    Dermatology; 2008; 217(4):365-73. PubMed ID: 18810241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of psoriasis with etretinate and acitretin: a follow up of actual use.
    Magis NL; Blummel JJ; Kerkhof PC; Gerritsen RM
    Eur J Dermatol; 2000; 10(7):517-21. PubMed ID: 11056421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
    Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
    Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
    Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
    Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study.
    Shapiro J; Cohen AD; David M; Hodak E; Chodik G; Viner A; Kremer E; Heymann A
    J Am Acad Dermatol; 2007 Apr; 56(4):629-34. PubMed ID: 17157411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.